Company news
Nanjing Leads Biolabs Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 3, 2026
Voluntary announcement part B of LBL-047 phase i study completes first dosing of a patient with systemic lupus erythematosus; novel BDCA2/TACI dual-targeting design enters clinical evaluation in patients
October 30, 2026
Voluntary announcement presentation of updated clinical and translational data of LBL-024 for extrapulmonary neuroendocrine carcinoma, biliary tract cancer and colorectal cancer at 2026 esmo
October 26, 2026
Voluntary announcement oral presentation of updated clinical data of LBL-034 for relapsed/refractory multiple myeloma at 2026 ESMO
October 25, 2026
Voluntary announcement phase ii study of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) as first-line treatment for gastric cancer progresses to expansion stage
October 20, 2026
Voluntary announcement abstracts of six studies published at 2026 ESMO
October 19, 2026
Voluntary announcement first patient enrolled in phase ib/II clinical trial of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) in combination therapy for metastatic colorectal cancer
October 16, 2026
Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Fast Track Designation by the U.S. FDA for first-line treatment of advanced biliary tract cancer
October 11, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
September 28, 2026
Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Orphan Drug Designation in Japan
September 28, 2026
2026 Interim report
September 23, 2026
Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations
September 21, 2026
Voluntary announcement pivotal registrational Phase IIb study of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) monotherapy in advanced EP-NEC selected as LBA and three studies selected for Proffered Paper presentations at 2026 ESMO
September 21, 2026
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
September 14, 2026
Voluntary announcement updated data from phase ii clinical study of lbl-024 (opamtistomig, pd-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line treatment for nsclc presented orally at wclc 2026
September 14, 2026
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
August 24, 2026
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
August 21, 2026
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
August 19, 2026
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals
August 5, 2026
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise
August 2, 2026
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Completes Patient Enrollment in Phase II Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors
July 30, 2026
Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline
July 13, 2026
Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
July 10, 2026
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
May 28, 2026
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
May 18, 2026
Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape
May 11, 2026
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
May 5, 2026
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies
April 21, 2026
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
April 9, 2026
Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
March 9, 2026
Global Development Accelerates: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Granted Fast Track Designation by FDA
January 15, 2026
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
December 23, 2025
Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
December 7, 2025
Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025
November 3, 2025
First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
September 22, 2025
Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig
September 12, 2025
Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial
August 25, 2025
Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma
August 14, 2025
Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering
July 24, 2025
Decks
- Investor Presentation (May 2026)
Investor deck · 62 slides · May 2026
- Leads Biolabs — Investor Presentation (November 2025)
Investor deck · 56 slides · November 2025